The list extends into the pharma industry, including Pfizer, GSK, and Novo Nordisk. On 14 November, Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet ...

Guggenheim raised the firm’s price target on Novo Nordisk (NVO) to DKK 798 from DKK 795 and keeps a Buy rating on the shares. The firm is ...

UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s shares closed last Friday at DKK637.20.

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) entered into oversold territory, hitting an RSI reading of 28 ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other stocks Jim Cramer recently discussed. In a recent episode of CNBC's Squawk On The Street ...

At Nordisk Insulinlaboratorium ... sister Wegovy—have transformed Novo into a global slimming juggernaut. In 2023, the company surpassed Parisian luxury brand LVMH to become the richest company ...